A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer

Oncogene, 2015 - nature.com
Targeted cancer therapies, although often effective, have limited utility owing to preexisting
primary or acquired secondary resistance. Consequently, agents are sometimes used in …
被引用次数：237 相关文章

A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer.

AL Kasinski, K Kelnar, C Stahlhut, E Orellana, J Zhao… - Oncogene, 2014 - europepmc.org
Targeted cancer therapies, while often effective, have limited utility due to preexisting
primary or acquired secondary resistance. Consequently, agents are sometimes used in …

A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer

AL Kasinski, K Kelnar, C Stahlhut, E Orellana, J Zhao… - Oncogene, 2015 - go.gale.com
Targeted cancer therapies, although often effective, have limited utility owing to preexisting
primary or acquired secondary resistance. Consequently, agents are sometimes used in …
[PDF] psu.edu

[PDF][PDF] A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer

AL Kasinski, K Kelnar, C Stahlhut, E Orellana, J Zhao… - Oncogene, 2015 - Citeseer
Targeted cancer therapies, while often effective, have limited utility due to preexisting
primary or acquired secondary resistance. Consequently, agents are sometimes used in …

[引用][C] A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer

AL Kasinski, K Kelnar, C Stahlhut, E Orellana, J Zhao… - Oncogene, 2014 - cir.nii.ac.jp

A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer.

AL Kasinski, K Kelnar, C Stahlhut, E Orellana… - …, 2015 - search.ebscohost.com
Targeted cancer therapies, although often effective, have limited utility owing to preexisting
primary or acquired secondary resistance. Consequently, agents are sometimes used in …
[PDF] researchgate.net

[PDF][PDF] A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer

AL Kasinski, K Kelnar, C Stahlhut, E Orellana, J Zhao… - Oncogene, 2014 - researchgate.net
Non-small cell lung cancer (NSCLC) is essentially untreatable, likely owing to accumulation
of mutations that affect the RAS and p53 pathways, and is the leading cause of cancer …
[PDF] purdue.edu

[PDF][PDF] A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer

AL Kasinski, K Kelnar, C Stahlhut, E Orellana, J Zhao… - Oncogene, 2014 - bio.purdue.edu
Non-small cell lung cancer (NSCLC) is essentially untreatable, likely owing to accumulation
of mutations that affect the RAS and p53 pathways, and is the leading cause of cancer …

A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer

AL Kasinski, K Kelnar, C Stahlhut, E Orellana… - …, 2015 - pubmed.ncbi.nlm.nih.gov
Targeted cancer therapies, although often effective, have limited utility owing to preexisting
primary or acquired secondary resistance. Consequently, agents are sometimes used in …
[HTML] nih.gov

[HTML][HTML] A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer

AL Kasinski, K Kelnar, C Stahlhut, E Orellana, J Zhao… - Oncogene, 2015 - ncbi.nlm.nih.gov
Targeted cancer therapies, while often effective, have limited utility due to preexisting
primary or acquired secondary resistance. Consequently, agents are sometimes used in …